Lutetium texaphyrin data

PCYC presented interim Phase I results with its photosensitizer in 19 patients with malignant melanoma, breast cancer, Kaposi's sarcoma, or invasive basal cell carcinoma, showing no skin phototoxicity and no systemic toxicities, with only transient discomfort at treatment sites. Tumor responses occurred at every dose level tested (0.5 to 2.5 umol/kg). Results were reported at the meeting of the American Society for Photobiology in Atlanta. ...